Dhooge C R, De Moerloose B M, Benoit Y C, Van Roy N, Laureys G G
Department of Pediatric Hemato-Oncology, University Hospital of Gent, Belgium.
Cancer. 1997 Oct 1;80(7):1250-7. doi: 10.1002/(sici)1097-0142(19971001)80:7<1250::aid-cncr8>3.0.co;2-o.
In cancer treated with chemotherapy, multidrug resistance is characterized by increased genetic expression of P-glycoprotein (P-gp), which acts as an ATP-dependent drug-efflux pump. However, the clinical significance of the expression of the multidrug resistance gene (MDR1) product P-gp in neuroblastoma (NB) is still a matter of debate. In this study, the role of the expression of P-gp in NB was evaluated.
NB tumor imprints and NB positive bone marrow smears from 23 children before and after multidrug chemotherapy were examined for P-gp expression by antialkaline phosphatase immunocytochemical analysis.
Before chemotherapy, only 10% of the NB samples showed positivity for P-gp. At diagnosis, no difference in P-gp expression was found between primary tumor cells and NB cells from metastases to bone marrow. P-gp positivity was only observed in patients with nonlocalized disease. P-gp positivity was never found in tumor cells that were histologically well differentiated. No clear correlation of P-gp positivity with poor prognostic parameters, such as chromosome 1p deletion or MYCN amplification, were found. Multidrug chemotherapy did not induce enhanced expression of P-gp in the neuroblasts. However, at clinical recurrence, P-gp expression was found in the metastatic NB cells of five of seven bone marrow samples examined.
The prognostic relevance of P-gp expression in NB was not clear from the results of this study. To resolve the uncertainties, a standardization of the methodology and more prospective studies are needed to determine whether routine analysis of P-gp is worth adding to the other prognostic parameters that are evaluated in NB patients. The finding that metastatic cells are capable of expressing MDR1, in contrast to the NB cells of the primary tumor, would certainly be an interesting topic for further study as work directed at understanding the progression to metastasis continues.
在接受化疗的癌症中,多药耐药的特征是P-糖蛋白(P-gp)基因表达增加,P-糖蛋白作为一种ATP依赖性药物外排泵发挥作用。然而,多药耐药基因(MDR1)产物P-gp在神经母细胞瘤(NB)中的表达的临床意义仍存在争议。在本研究中,评估了P-gp表达在NB中的作用。
采用抗碱性磷酸酶免疫细胞化学分析法,检测了23例接受多药化疗前后儿童的NB肿瘤印片和NB阳性骨髓涂片的P-gp表达。
化疗前,仅10%的NB样本显示P-gp阳性。在诊断时,原发性肿瘤细胞与骨髓转移灶中的NB细胞之间的P-gp表达无差异。P-gp阳性仅在非局限性疾病患者中观察到。在组织学上分化良好的肿瘤细胞中从未发现P-gp阳性。未发现P-gp阳性与不良预后参数(如1号染色体p缺失或MYCN扩增)有明显相关性。多药化疗未诱导神经母细胞中P-gp表达增强。然而,在临床复发时,在检测的7份骨髓样本中的5份转移性NB细胞中发现了P-gp表达。
本研究结果尚不清楚P-gp表达在NB中的预后相关性。为了解决这些不确定性,需要对方法进行标准化并开展更多前瞻性研究,以确定P-gp的常规分析是否值得添加到对NB患者进行评估的其他预后参数中。与原发性肿瘤的NB细胞相比,转移细胞能够表达MDR1这一发现,随着针对理解转移进展的研究不断深入,肯定会成为进一步研究的一个有趣课题。